Pharmacia & Upjohn Inc · 425 · Pharmacia & Upjohn Inc · On 3/23/00

Filed On 3/23/00   ·   SEC File 1-11557   ·   Accession Number 950123-0-2624

Business-Combination Transaction Communication   ·   Rule 425
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 425         Pharmacia & Upjohn, Inc.                               9     20K 

425
1st Page of 9
TOC
Top
Previous
Next
Bottom
Just 1st
 
Sponsored Ads...


                                               Filed by Pharmacia & Upjohn, Inc.
                           Pursuant to Rule 425 under the Securities Act of 1933
                                        and deemed filed pursuant to Rule 14a-12
                                          of the Securities Exchange Act of 1934

                                       Subject Company: Pharmacia & Upjohn, Inc.
                                                   Commission File No. 001-11557

The following is a transcript of a videotape presentation used at Pharmacia &   
Upjohn, Inc.'s special stockholders' meeting on March 23, 2000.                 

[LOGO: Camptosar irinotecan HCI injection]                                      

[Zyvox]                                                                         

[Arthrotec]                                                                     

[LOGO: Xalatan latanoprost ophthalmic solution]                                 

[LOGO: Celebrex]                                                                

 There is a powerful new competitor in the global pharmaceutical
industry. Brought together and driven by a single unifying vision of growth.    
This global force is comprised of two rapidly growing pharmaceutical companies. 
In an age where consolidation is often driven by weakness, Pharmacia & Upjohn   
and Monsanto are forging a merger of strength. [LOGO: Pharmacia & Upjohn] [LOGO:
MONSANTO].                                                                      

[BULLET LIST:                                                                   

Robust Product Flow                                                             

Limited Patent Exposure                                                         

Broad Technologies                                                              

Proven Management]                                                              

 -1-

425
2nd Page of 9
TOC
1st
Previous
Next
Bottom
Just 2nd

With robust new product flow, limited patent exposure, a broad
technology platform and a management team that delivers results, this new       
company will be among the most dynamic pharmaceutical enterprises in the world  
today. With its core emphasis on pharmaceuticals, this powerful new company will
be aptly named Pharmacia. [LOGO: PHARMACIA]                                     

       [BULLET POINT: Robust Product Flow] New product flow is the lifeblood
of a fast growing pharmaceutical company and the key driver to this new         
company's current and future earnings growth. The current array of blockbuster  
drugs includes Celebrex [LOGO: Celebrex], Xalatan [LOGO: Xalatan latanoprost    
ophthalmic solution], Detrol [LOGO: Detrol tolferodine tartrate tablets], and   
Camptosar [LOGO: Camptosar irinotecan HCI injection].                           

[LOGO: Celebrex] In its first year on the market, Celebrex has
surpassed all other drug launches in history. [Lee S. Simon, MD, Division of    
Rheumatology and Metabolic Bone Disease, Associate Professor of Medicine,       
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA]: "As  
someone who sees patients, of these the most exciting of times, to have         
available COX-2 specific inhibitors has really changed my world and I believe it
has changed my patients' world. I have now been able to use a drug called       
Celebrex, which truly fulfills the needs that we have. This is an               
anti-inflammatory, an analgesic drug, which does not convey the same risk as    
equally effective drugs that have been available for many years. These drugs are
going to win                                                                    

 -2-

425
3rd Page of 9
TOC
1st
Previous
Next
Bottom
Just 3rd

hands down every time and Celebrex, being at the forefront of its development,  
will be the one that most people will identify as the drug to use."             

   [LOGO: Xalatan] [Stephen A. Obstbaum, MD, Director, Department of
Ophthalmology, Lenox Hill Hospital, New York, NY]: "Now they've made an         
incredible contribution with the introduction of Xalatan which is really a      
remarkable drug. It's going to help millions of patients worldwide. Up until    
several years ago, we were rather limited in the types of drugs we could use to 
treat glaucoma. Xalatan is very different from any of the other drugs that we   
have used in the past. Now, one of the things that occurs with many types of    
glaucoma medications is that with the passage of time there's a loss of effect  
of the drug. This has not been demonstrated with Xalatan. So it really has      
created an incredible impact on the way we approach the disease and the fact    
that the company has pursued, with such diligence, the development of this drug 
is remarkable. It's remarkable, really, in the annals of modern pharmaceutical  
development. Here a drug comes on the market, three years later it's a market   
leader. That's, that's superb."                                                 

     [LOGO: Detrol] The introduction of Detrol completely transformed an
under- diagnosed condition into a widely-recognized disease called overactive   
bladder. [BAR CHART: Worldwide OAB Market, Vast and Undertreated Disease, LOGO  
Detrol, horizontal axis indicates number of people, vertical axis indicates     
status:                                                                         

STATUS               NUMBER OF PEOPLE       

Patients             50 + million           

Diagnosed            15 million             

 -3-

425
4th Page of 9
TOC
1st
Previous
Next
Bottom
Just 4th

Treated with Rx       2.5-5 million                   

Treated with Detrol   3 million]                      

To take Detrol to the next level, this partnership is already realizing an      
important synergy. [COLUMN CHART: US Overactive Bladder Sales Force Size, LOGO  
Detrol, horizontal axis indicates "Competitor" and "Detrol", vertical axis      
indicates sales force size:                                                     

COMPETITOR             DETROL                         

       approximately 900      Pharmacia & Upjohn approximately 1200,
                           Monsanto Company approximately 600,
 Pharmacia
                      Corporation approximately 1800

By strengthening the sales force through a powerful co-promotion agreement, the 
company is effectively doubling the sales force of the nearest competitor.      

     [LOGO: Camptosar irinotecan HCI injection] [Daniel D. Von Hoff, MD,
Professor of Medicine, Director, Arizona Cancer Center, University of Arizona   
Health Sciences Center, Tucson, AZ]: "I've been a medical oncologist for 25     
years and things have changed mostly in the last five years. Camptosar is one of
the drugs that signaled a change. Every year more people die of cancer in the   
United States than in all the wars we fought this century. It's really          
remarkable the loss that we have. Each day 1,500 patients die of cancer.        
Camptosar is the first drug ever to make an impact on survival of patients with 
colon cancer, even after they've progressed on first-line therapy. In addition  
to having activity in patients with colon cancer, the drug clearly has activity 
in patients with                                                                

 -4-

425
5th Page of 9
TOC
1st
Previous
Next
Bottom
Just 5th

pancreatic cancer, brain tumors, patients with gastric cancer, cervical cancer, 
and one that's totally untapped is tremendous activity in patients with lung    
cancer."                                                                        

        [BULLET POINT: Limited Patent Exposure] Based on data from IMS Health,
the world-leading provider of pharmaceutical information, over the next five    
years Pharmacia will have amongst the lowest exposure to patent expiration in   
the pharmaceutical industry.                                                    

[CHART: Patent Expiration                                                       

Zyvox             2014                                                          

Celebrex          2013                                                          

Detrol            2012                                                          

Xalatan           2011                                                          

Camptosar         2007]                                                         

   [BULLET POINT: Broad Technologies] As these two technology-driven
companies build a unique market-leading business, they will exploit their broad 
technology platforms in six core therapeutic areas.                             

[BULLET LIST:                                                                   

Oncology                                                                        

Arthritis/Inflammation                                                          

Metabolic Diseases                                                              

CNS Disease                                                                     

Infectious Diseases                                                             

 -5-

425
6th Page of 9
TOC
1st
Previous
Next
Bottom
Just 6th

Cardiovascular Diseases]                                                        

  [Zyvox] Zyvox will be the first major new product launch for the
combined company. [Gary A. Noskin, MD, Associate Professor of Medicine, Medical 
Director, Infection Control / Healthcare Epidemiology, Division of Infectious   
Diseases, Northwestern University Medical School, Northwestern University,      
Chicago, IL]: "Zyvox is a remarkable new antibiotic. It has the potential to    
completely change our treatment of patients with bacterial infections. The issue
of bacterial resistance has really reached a crisis proportion. It's hard to    
believe that in the year 2000 we have patients infected with bacteria for which 
there is no therapy and what's particularly interesting about Zyvox that makes  
it different than other antibiotics is the mechanism of resistance is such that 
resistance occurs very infrequently. In fact, in over 5,000 clinical ISOLATES,  
we have not yet seen one organism that's resisted to it. One of the major       
advantages of Zyvox is that it can be used both intravenously and orally. There 
are no currently available antibiotics in the near stages of development that   
are going to allow us to treat patients in the hospital and then orally as an   
outpatient. I think Zyvox has the potential to become the primary treatment of  
choice for severe gram-positive infections, especially in hospitalized          
patients."                                                                      

  [Eplerenone] The new company is also aggressively pursuing novel
targets in cardiology which are not yet being pursued by other companies.       
[Gordon H. Williams, MD, Chief, Endocrinology, Hypertension Division, Professor 
of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA]: 
"Cardiovascular disease                                                         

 -6-

425
7th Page of 9
TOC
1st
Previous
Next
Bottom
Just 7th

worldwide is increasing in probably epidemic fashion. There are now more than   
200 million people in the world who have hypertension. There are close to 10    
million people who have heart failure. It is likely that an OUTERSTRONE?        
receptor antagonist that is specific will be a keystone in the treatment of     
cardiovascular disease. Eplerenone which is in Phase 3 clinical trials now, is  
such an agent and it is the first of a class of agents which are specific       
OUTERSTRONE receptor antagonists.                                               

   [Oncology Platform] Cancer remains one of our greatest healthcare
challenges. Pharmacia is redefining oncology by aggressively pursuing new       
biomedical technologies. [Professor Daniel D. Von Hoff]: "Pharmacia & Upjohn has
the most exciting pipeline of all oncology companies. It's kind of funny I'm    
referring to them as an oncology company - I know they have lots of other things
- but they have been outstanding in their development of new therapeutics for   
patients."                                                                      

        With the acquisition of Sugen, a west coast biotech company, Pharmacia
took a bold step towards its vision of becoming the new oncology challenger.    
Sugen is a leader in innovative cell signaling technology and has an advanced   
pipeline of oncology products, including molecule 5416. The ability to inhibit  
ANGIOGENESIS is opening up new frontiers to less toxic, more targeted treatments
for cancer. SU 5416 has the potential to become the first ANGIOGENESIS inhibitor
to reach the market.                                                            

         [COX - 2 Platform] [Professor Lee S. Simon]: "Since the observation was
made that there is a COX-1 and a COX-2 many people have been trying to define   
where COX- 2 is important. To be able to have drugs with such a safety profile, 
to be able to                                                                   

 -7-

425
8th Page of 9
TOC
1st
Previous
Next
Bottom
Just 8th

potentially be used in not only arthritis but perhaps in the treatment of cancer
or prevention of cancer or even in the treatment of Alzheimer's disease is,     
without a doubt, mind boggling."                                                

       [BULLET POINT: Proven Management]. To maximize the full value of this
broad technology platform, an experienced management team, with a keen sense of 
vision and the ability to see it through has been assembled. [NAME LIST: Fred   
Hassan, Richard De Schutter, Christopher Coughlin, Philip Needleman, PhD.,      
Hendrik Verfaillie, Gary Crittenden, Goran Ando, Carrie Cox, Alan Heller, Tim   
Rothwell]. This management team is dedicated to delivering on its vision of     
growth.                                                                         

[LOGO: Xalatan latanoprost ophthalmic solution]                                 

[LOGO: Camptosar irinotecan HCI injection]                                      

[Zyvox]                                                                         

[LOGO: Arthrotec]                                                               

[LOGO: Xalatan latanoprost ophthalmic solution]                                 

[LOGO: Celebrex]                                                                

[LOGO: PHARMACIA]                                                               

 ***************

These materials contain certain forward-looking statements, including, among    
other things, statements regarding each company's or the combined company's     
anticipated financial or product performance, pipeline, plans for growth,       
expected cost savings from the merger and other statements relating to future   
events. These forward-looking statements are based on current expectations, but 
actual results may differ materially from anticipated future events or results. 
Certain factors which could cause each company's individual and the combined    
company's actual results to differ materially from expected and historical      
results are described in Monsanto's and Pharmacia & Upjohn's periodic reports   
filed with the Securities and Exchange Commission, including Monsanto's and     
Pharmacia & Upjohn's 1999 annual reports, on Forms 10-K and Exhibits 99 thereto,

 -8-

425
Last Page of 9
TOC
1st
Previous
Next
Bottom
Just 9th

respectively, and the definitive joint proxy statement/prospectus relating to   
the merger filed by each of Monsanto Company and Pharmacia & Upjohn on February 
22, 2000.                                                                       

The forward-looking information included in these materials filed pursuant to   
Rule 425 under the Securities Act of 1933 filed on March 23, 2000, has been     
prepared by, and is the responsibility of, the management of Pharmacia & Upjohn.
The forward-looking information is not intended to comply with the presentation 
and disclosure guidelines for prospective financial information of the          
Securities and Exchange Commission or the American Institute of Certified Public
Accountants.                                                                    

Monsanto and Pharmacia & Upjohn have filed a definitive joint proxy statement   
and prospectus with the United States Securities and Exchange Commission (the   
"SEC"). WE URGE INVESTORS TO READ THE DEFINITIVE JOINT PROXY                    
STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS TO BE FILED WITH THE SEC, 
BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors will be able to obtain the
documents free of charge at the SEC's website, www.sec.gov. In addition,        
documents filed with the SEC by Monsanto will be available free of charge from  
the Secretary of Monsanto at 800 North Lindbergh Blvd., St. Louis, Missouri     
63167, Telephone (314) 694-1000. Documents filed with the SEC by Pharmacia &    
Upjohn will be available free of charge from the Corporate Secretary of         
Pharmacia & Upjohn, 100 Route 206 North, Peapack, NJ 07977, Telephone           
(888)768-5501. READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS CAREFULLY   
BEFORE MAKING A DECISION CONCERNING THE MERGER.                                 

Monsanto, its directors, executive officers and certain other members of        
management and employees may be soliciting proxies from Monsanto stockholders in
favor of the merger. Information concerning the participants in the solicitation
is set forth in the Current Report on Form 8-K filed by Monsanto with the SEC on
January 25, 2000.                                                               

Pharmacia & Upjohn, its directors, executive officers and certain other members 
of management and employees may be soliciting proxies from Pharmacia & Upjohn   
stockholders in favor of the merger. Information concerning the participants in 
the solicitation is included in filings under Rule 425 made by Pharmacia &      
Upjohn with the SEC on January 27, 2000.                                        

 -9-

Dates Referenced Herein   and   Documents Incorporated By Reference

				Referenced-On Page
This 425 Filing		Date		First		Last			Other Filings
		1/25/00		9					8-K
		1/27/00		9					425
		2/22/00		9					425, DEFM14A
Filed On / Filed As Of		3/23/00		1		9
Top									List All Filings